Recombinant Human RANK/TNFRSF11A Fc Chimera Protein, CF | R&D Systems 683-RK-100 product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human RANK/TNFRSF11A Fc Chimera Protein, CF

catalog :

683-RK-100

quantity :

100 ug

price :

447 USD

more info or order :

R&D Systems product webpage

citations: 7

Reference
Xiong J, Cawley K, Piemontese M, Fujiwara Y, Zhao H, Goellner J, et al. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat Commun. 2018;9:2909 pubmed publisher
Savage J, Pulsipher A, Rao N, Kennedy T, Prestwich G, Ryan M, et al. A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis. PLoS ONE. 2016;11:e0157310 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
Colucci S, Brunetti G, Mori G, Oranger A, Centonze M, Mori C, et al. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia. 2009;23:2139-46 pubmed publisher
Colucci S, Brunetti G, Cantatore F, Oranger A, Mori G, Quarta L, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007;212:47-55 pubmed
Edwards J, Sun S, Locklin R, Shipman C, Adamopoulos I, Athanasou N, et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum. 2006;54:1451-62 pubmed
Okuma K, Dalton K, Buonocore L, Ramsburg E, Rose J. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. J Virol. 2003;77:8562-9 pubmed

product information

brand :

R&D Systems, a Bio-Techne Brand

catalog number base :

683-RK

SKU :

683-RK-100

product name :

Recombinant Human RANK/TNFRSF11A Fc Chimera Protein, CF

Description :

The Recombinant Human RANK/TNFRSF11A Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human RANK/TNFRSF11A Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

RANK/TNFRSF11A

category :

Proteins and Enzymes

unit size :

100 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

60 kDa, reducing conditions

theoretical molecular weight :

48 kDa (monomer)

gene symbol :

TNFRSF11A

details of functionality :

Measured by its ability to inhibit TRANCE-induced osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 0.005-0.035 µg/mL in the presence of 2 ng/mL of rmTRANCE (Catalog # 462-TEC).

endotoxin note :

<0.01 EU per 1 µg of the protein by the LAL method.

accessionNumbers :

Q9Y6Q6.1

applications :

Bioactivity

source :

NS0-derived Recombinant Human RANK/TNFRSF11A Fc Chimera Protein

USD :

447 USD

alt names :

CD265, CD265 antigen, FEO, loss of heterozygosity, 18, chromosomal region 1, ODFR, ODFROSTS, OFE, OPTB7, Osteoclast differentiation factor receptor, PDB2, RANKLOH18CR1, Receptor activator of NF-KB, receptor activator of nuclear factor-kappa B, TNFRSF11A, TRANCE R, TRANCER, tumor necrosis factor receptor superfamily member 11A, tumor necrosis factor receptor superfamily, member 11a, activator of NFKB, tumor necrosis factor receptor superfamily, member 11a, NFKB activator

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage